NCT00014690View on ClinicalTrials.gov

ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 2001

Study Completion Date

February 29, 2004

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

plevitrexed

DRUG

topotecan hydrochloride

Trial Locations (1)

19850-5437

AstraZeneca Pharmaceuticals LP, Wilmington

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY